Introduction
Postmastectomy arm lymphedema is a severe complication of the local treatment of breast cancer. The reported incidence varies widely, but recent studies indicate a range of 10%-33% [1] [2] [3] with 15% of cases of a moderate to severe degree [2] .
Lymphedema complications include predisposition to infection, functional impairment, psychological morbidity [4] and, rarely, secondary malignancies [5] .
Conservative treatment of postmastectomy lymphedema can be divided into two broad categories: pharmacological and physical [6] . The latter includes compression garments, manual lymphatic drainage and intermittent pneumatic compression. However, the lack of an objectively-reproducible and widely acceptable method of assessing the degree of lymphedema, and the paucity of comparative clinical trials generate confusion regarding the actual effectiveness of these methods in the treatment of postmastectomy lymphedema. Pneumatic compression is one of the most commonly used physical modalities [7] . However, despite its widely-disseminated use, its efficacy has not yet been demonstrated in randomized studies and thus it cannot be considered a standard therapy for postmastectomy lymphedema.
The aim of the present phase III study was to compare intermittent pneumatic compression to no treatment (i.e., hygienic guidelines only) in the management of patients with postmastectomy lymphedema.
Patients and methods
Patients were eligible if the following criteria were met: prior to monolateral radical breast surgery with axillary node dissection for stage I-III breast cancer; no evidence of local or distant relapse; more than 10 cm difference between the circumference of affected and normal limbs (see below for the assessment method); no signs or symptoms of lymphangitis of the arm; no other serious or psychiatric illness that would preclude appropriate treatment or follow-up. Patients who had received prior specific therapy for lymphedema of the arm, or had had bilateral breast surgery and/or bilateral axillary node dissection, were excluded. The study was approved by the Protocol Review Committee and Ethics Committee of Istituto Nazionale per la Ricerca sul Cancro Genova, Italy. Informed consent was obtained from all patients before study entry.
Lymphedema was denned by an absolute increase in circumference of the affected limb in comparison with the normal one. Circumferences are recorded in seven matching points: hand, wrist, lower one-third of the forearm, upper one-third of the forearm, elbow, lower one-third of the arm, upper one-third of the arm. The differences in circumference measurements between limbs at each point were added together and the result was designated 'delta'. Only patients with a baseline delta (delta bas ) value >10 cm were considered to have a clinically significant lymphedema, and admitted into the trial. This method of assessment of lymphedema is less cumbersome than volume measurement with instrumental devices or water displacement, and was used in our previous studies [8, 9] All patients received guidelines about skin care and prophylaxis for the edematous limb. Recommendations included careful disinfection of any wound or scratch, use of gloves during gardening, avoidance of weight gain, of venipuncture in the affected limb, of prolonged sun exposure, of carrying heavy weights [10] .
Patients were randomized to receive no treatment (control group) or to intermittent pneumatic compression (PC group). Pneumatic compression was applied in two cycles of two weeks each, separated by a five-week interval. Each cycle consisted of five two-hour sessions per week at a constant pressure of 60 mmHg. No other concomitant physical treatment was allowed during the period of the study.
Before the start of therapy all patients underwent physical examination, and instrumental and clinical evaluations to exclude tumor relapse, and measurement of limbs to assess deltabas value. After nine weeks, or at the completion of pneumatic compression in the PC group, all patients were re-evaluated by physical examination and final delta (delta end ) value measurement.
At the end of treatment in the PC group and at the ninth week in the control group, response to therapy was assessed, as defined by the percentage variation of the final delta compared to baseline. According to our previously used definition [8] , objective response was defined as a reduction of delta ^ 25% compared to initial value; progression as an increase of delta > 25%; any other result was defined as stabilization.
Statistical considerations
The results were evaluated by assessment of the absolute mean variation of delta values, and by the clinical response according to the definition reported above. Sample size was calculated by the following assumptions. We considered that the proportion of responding patients in the control arm could be 10%, and based on the results previously reported with the use of the elastic sleeve alone [8] , we were interested in observing a 40% proportion of responding patients in the PC group. For alpha error = 0.05 and an 85% power, we had to randomize 35 patients per group.
Randomization was performed by telephone call to the Clinical Epidemiology and Trials Office of our Institute, which prepared and kept the randomization lists.
In analyzing response to treatment the 'intent to treat'criterion was applied. Therefore, all randomized patients were evaluated. Data are reported as mean values 1 standard deviation.
Results
Eighty patients entered the study (Table 1) . Baseline characteristics were similar in the two groups, including previous surgery, radiotherapy and chemotherapy. Seventeen (42.5%) patients in the control group and 21 (52.5%) patients in the PC group had gained weight after mastectomy, for mean gains of 4.4 ± 2.8 kg and 4.7 ± 2.3 kg, respectively. At study entry, lymphedema was of mild to moderate degree in all patients, with the onset less than one year previously.
Thirteen patients were unevaluable for the following reasons: in five patients in the control group, local (one patient) or distant relapse (one patient) during the study period, lost to follow-up (three patients); and in eight patients in the PC group: local relapse (one patient), intercurrent disease (one patient), refusal of PC treat- Abbreviation: BMI -body mass index. Eight patients (20%, 95% CI: 9%-36%) in the control group, and 10 patients (25%, 95% CI: 13%-41%) in the PC group had reduction ^25% of their lymphedema (P = 0.59) ( Table 2) . Thirty-five patients in the control group and 32 patients in the PC group were evaluable in terms of absolute delta value variations. In these patients, mean delta bas values were 14.6 ± 4.4, and 16.1 ± 5.4 in the control and PC groups, respectively; at the end of study mean delta end values were 14.1 ± 5.6 cm, and 14.2 ± 6.0 cm, in the control and PC groups, respectively ( Figure  1 ). Within-group comparison showed that the PC group had obtained a statistically significant mean decrease in delta value (16.1 ± 5.4 at baseline vs. 14.2 ± 6 at the end of treatment, P -0.009), while in the control group there was no significant change (14.6 ± 4.4 vs. 14.1 ± 5.6, P -0.33). The difference between the two groups in final delta values, however, was not significant (P = 0.084) even after correction for basal values. A univariate analysis of subgroups of patients, divided according to prior treatments (radiotherapy, chemotherapy, type of surgery) or other characteristics (prior lymphangitis, age, body mass index) identified no significant prognostic factors for response.
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Discussion
Although several physical methods of treatment of postmastectomy lymphedema are used in clinical practice, few randomized studies have been performed to substantiate their value. We previously reported no advantage for electrically-stimulated lymphatic drainage compared to the simple use of an elastic sleeve [8] . The study showed that wearing an elastic sleeve led to a 17% mean reduction of lymphedema. This reduction was statistically significant but of little clinical importance. Indeed, the vast majority of patients in the study, i.e., nearly 70%, did not achieve what we consider a clinically meaningful result, i.e., a reduction of at least 25% of limb girth. These results prompted us to prospectively evaluate, within the rigorous framework of a randomized trial, another widely used physical method, namely, pneumatic compression. Again, the method proved to be of limited clinical significance. Patients randomized to receive pneumatic compression obtained a 11% (1.9 cm as a mean) reduction of their lymphedema, but the clinically significant target of a 25% reduction of lymphedema was reached by almost the same percentage of patients in the control group (20% in the control group vs. 25% in the PC group, P = 0.59).
Data from non-randomized studies suggest that complex physical therapy, including special lymphatic massage, compression bandaging and compression garments, skin care, and special exercises, induces an edema reduction ranging from 51% to 81%, depending on the grade of lymphedema [2] . However, these results, from nonrandomized studies, may overestimate the benefit of physical therapy due to various types of biases affecting retrospective evaluations. Data from our two randomized studies [8 and present study] show no clear advantage for instrumental physical therapies such as electricallystimulated lymphatic drainage or pneumatic compression in comparison to simpler methods such as wearing of an elastic sleeve. Moreover, our data indicated that in 20% of patients with lymphedema of mild or moderate degree, as for instance in the population enrolled in this study, a reduction of edema can be observed in the absence of any active treatment; adherence to hygienic guidelines could be the most effective part of the management of lymphedema. This reinforces our opinion that only controlled studies can elucidate the actual role of any clinical intervention in this disease.
Since the benefit of physical methods in the treatment of lymphedema can be expected to be quite low, other methods of treatment could be proposed to patients. Among the possible pharmacological treatments of lymphedema, promising results were reported with the use of 5,6 benzo-[a] pyrone [11] . This drug reduces the volume of high-protein edema fluid, stimulating proteolysis; in a randomized study it has been reported to be capable of slowly reducing lymphedema of limbs. Flavonoids, such as benzo-[y] pyrone, are also considered beneficial in the treatment of lymphedema [12] . However, the action of these drugs is slow and they cannot restore the lymphedematous arm to a normal condition (the mean amount of edema fluid in the arm remains at 26% above normal); side effects are also possible.
Overall, prevention seems to remain the best way to manage postmastectomy lymphedema. In early breast cancer, axillary dissection used to represent an important staging procedure, making it possible to choose an optimal systemic therapy. However, recent data suggest that nearly all patients with tumors > 1 cm will require systemic treatment, regardless of nodal status [13] . Moreover, other studies show that sentinel node biopsy may soon become a reliable substitute for routine axillary dissection [14, 15] . Therefore, avoiding axillary clearance, which is the leading cause of postmastectomy lymphedema, may decrease the morbidity of breast cancer surgery without compromising patient care. Meanwhile, patients affected with mild lymphedema should be advised to follow hygienic skin care, to avoid weight gain and possibly to use an elastic sleeve. Patients with more severe lymphedema could be candidates for pharmacological treatments. The roles of manual lymph drainage and the combined or sequential use of several treatments remain to be determined in properly designed trials.
